The high return of drugs should be based on the premise of super-high capital investment, R&D risk and R&D cycle of several decades, so as to have the opportunity to invest in R&D again and form a virtuous circle.
Based on such industrial characteristics, in order to ensure the core competitiveness of drugs-"clinical value", how to establish a rapid and effective early comprehensive evaluation system, and discover and predict the potential safety and possible clinical effectiveness of lead compounds with biological activity as soon as possible is the core issue of global new drug research and development.
Among all the commodities, medicine is a very special commodity. Although pharmaceutical R&D enterprises need to obtain certain commercial profits, "clinical value" is more important.
Through an enterprise's investment in drug research and development, we can see its value pursuit. In 200 1 year, when most domestic pharmaceutical companies were still in the stage of making "generic drugs" with expired patents or transforming some chemical structures of the original drugs, such a team resolutely gave up their stable life in the United States and returned to the motherland to start a business, with the intention of developing "original new drugs" exclusively for China.
Now, after 2 1 year development, the team has not only realized its own butterfly change, but also independently developed the world's first subtype selective HDAC inhibitor-Chidamine, which has added a lot of color to the clinical treatment of recurrent and refractory peripheral T-cell lymphoma (PTCL) in China.